Literature DB >> 20096141

Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.

John S Albin1, Reuben S Harris.   

Abstract

Restriction factors are natural cellular proteins that defend individual cells from viral infection. These factors include the APOBEC3 family of DNA cytidine deaminases, which restrict the infectivity of HIV-1 by hypermutating viral cDNA and inhibiting reverse transcription and integration. HIV-1 thwarts this restriction activity through its accessory protein virion infectivity factor (Vif), which uses multiple mechanisms to prevent APOBEC3 proteins such as APOBEC3G and APOBEC3F from entering viral particles. Here, we review the basic biology of the interactions between human APOBEC3 proteins and HIV-1 Vif. We also summarise, for the first time, current clinical data on the in vivo effects of APOBEC3 proteins, and survey strategies and progress towards developing therapeutics aimed at the APOBEC3-Vif axis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20096141      PMCID: PMC2860793          DOI: 10.1017/S1462399409001343

Source DB:  PubMed          Journal:  Expert Rev Mol Med        ISSN: 1462-3994            Impact factor:   5.600


  168 in total

1.  An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22.

Authors:  Adam Jarmuz; Ann Chester; Jayne Bayliss; Jane Gisbourne; Ian Dunham; James Scott; Naveenan Navaratnam
Journal:  Genomics       Date:  2002-03       Impact factor: 5.736

2.  Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation.

Authors:  Andrew Mehle; Joao Goncalves; Mariana Santa-Marta; Mark McPike; Dana Gabuzda
Journal:  Genes Dev       Date:  2004-12-01       Impact factor: 11.361

3.  Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1.

Authors:  Eri Miyagi; Sandrine Opi; Hiroaki Takeuchi; Mohammad Khan; Ritu Goila-Gaur; Sandra Kao; Klaus Strebel
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

Review 4.  Hepatitis B: modern concepts in pathogenesis--APOBEC3 cytidine deaminases as effectors in innate immunity against the hepatitis B virus.

Authors:  Marianne Bonvin; Jobst Greeve
Journal:  Curr Opin Infect Dis       Date:  2008-06       Impact factor: 4.915

5.  Functional domain organization of human APOBEC3G.

Authors:  Barry D Gooch; Bryan R Cullen
Journal:  Virology       Date:  2008-07-18       Impact factor: 3.616

6.  Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals.

Authors:  S Yamanaka; M E Balestra; L D Ferrell; J Fan; K S Arnold; S Taylor; J M Taylor; T L Innerarity
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

7.  APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells.

Authors:  Hal P Bogerd; Heather L Wiegand; Brian P Doehle; Kira K Lueders; Bryan R Cullen
Journal:  Nucleic Acids Res       Date:  2006-01-10       Impact factor: 16.971

8.  RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1.

Authors:  Hendrik Huthoff; Flavia Autore; Sarah Gallois-Montbrun; Franca Fraternali; Michael H Malim
Journal:  PLoS Pathog       Date:  2009-03-06       Impact factor: 6.823

9.  APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.

Authors:  Yanxing Han; Xiaojun Wang; Ying Dang; Yong-Hui Zheng
Journal:  PLoS Pathog       Date:  2008-07-04       Impact factor: 6.823

10.  APOBEC3G-UBA2 fusion as a potential strategy for stable expression of APOBEC3G and inhibition of HIV-1 replication.

Authors:  Lin Li; Dong Liang; Jing-yun Li; Richard Y Zhao
Journal:  Retrovirology       Date:  2008-08-04       Impact factor: 4.602

View more
  116 in total

1.  A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif.

Authors:  John S Albin; Rebecca S LaRue; Jessalyn A Weaver; William L Brown; Keisuke Shindo; Elena Harjes; Hiroshi Matsuo; Reuben S Harris
Journal:  J Biol Chem       Date:  2010-10-22       Impact factor: 5.157

2.  The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.

Authors:  Mawuena Binka; Marcel Ooms; Myeika Steward; Viviana Simon
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

3.  HIV type 1 viral infectivity factor and the RUNX transcription factors interact with core binding factor β on genetically distinct surfaces.

Authors:  Judd F Hultquist; Rebecca M McDougle; Brett D Anderson; Reuben S Harris
Journal:  AIDS Res Hum Retroviruses       Date:  2012-08-13       Impact factor: 2.205

4.  Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1.

Authors:  Judd F Hultquist; Joy A Lengyel; Eric W Refsland; Rebecca S LaRue; Lela Lackey; William L Brown; Reuben S Harris
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

5.  Structural Insights into HIV-1 Vif-APOBEC3F Interaction.

Authors:  Masaaki Nakashima; Hirotaka Ode; Takashi Kawamura; Shingo Kitamura; Yuriko Naganawa; Hiroaki Awazu; Shinya Tsuzuki; Kazuhiro Matsuoka; Michiko Nemoto; Atsuko Hachiya; Wataru Sugiura; Yoshiyuki Yokomaku; Nobuhisa Watanabe; Yasumasa Iwatani
Journal:  J Virol       Date:  2015-11-04       Impact factor: 5.103

6.  APOBEC3B is an enzymatic source of mutation in breast cancer.

Authors:  Michael B Burns; Lela Lackey; Michael A Carpenter; Anurag Rathore; Allison M Land; Brandon Leonard; Eric W Refsland; Delshanee Kotandeniya; Natalia Tretyakova; Jason B Nikas; Douglas Yee; Nuri A Temiz; Duncan E Donohue; Rebecca M McDougle; William L Brown; Emily K Law; Reuben S Harris
Journal:  Nature       Date:  2013-02-06       Impact factor: 49.962

7.  CBFβ enhances de novo protein biosynthesis of its binding partners HIV-1 Vif and RUNX1 and potentiates the Vif-induced degradation of APOBEC3G.

Authors:  Eri Miyagi; Sandra Kao; Venkat Yedavalli; Klaus Strebel
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

8.  APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.

Authors:  Chawaree Chaipan; Jessica L Smith; Wei-Shau Hu; Vinay K Pathak
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

9.  Interleukin-32 isoforms: expression, interaction with interferon-regulated genes and clinical significance in chronically HIV-1-infected patients.

Authors:  Katia Monteleone; Pierluigi Di Maio; Giulia Cacciotti; Francesca Falasca; Maurizio Fraulo; Mario Falciano; Ivano Mezzaroma; Gabriella D'Ettorre; Ombretta Turriziani; Carolina Scagnolari
Journal:  Med Microbiol Immunol       Date:  2014-02-20       Impact factor: 3.402

10.  Core Binding Factor β Protects HIV, Type 1 Accessory Protein Viral Infectivity Factor from MDM2-mediated Degradation.

Authors:  Yusuke Matsui; Keisuke Shindo; Kayoko Nagata; Noriyoshi Yoshinaga; Kotaro Shirakawa; Masayuki Kobayashi; Akifumi Takaori-Kondo
Journal:  J Biol Chem       Date:  2016-10-07       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.